Breaking News Instant updates and real-time market news.

YASKY

Yaskawa Electric

$98.42 /

+0.22 (+0.22%)

09:30
06/30/21
06/30
09:30
06/30/21
09:30

Yaskawa Electric upgraded to Conviction Buy from Buy at Goldman Sachs

Goldman Sachs analyst Yuichiro Isayama added Yaskawa Electric to the firm's Conviction List and keeps a Buy rating on the shares with an unchanged price target of 7,000 yen, implying upside of almost 30%. The analyst thinks stronger than expected short-term orders and earnings trends will help drive up the share price.

YASKY Yaskawa Electric
$98.42 /

+0.22 (+0.22%)

04/12/21 Jefferies
Yaskawa Electric downgraded to Hold from Buy at Jefferies
01/04/21 Goldman Sachs
Yaskawa Electric upgraded to Buy from Neutral at Goldman Sachs
10/22/20 SMBC Nikko
Yaskawa Electric upgraded to Neutral from Underperform at SMBC Nikko
07/21/20 Daiwa
Yaskawa Electric downgraded to Neutral from Outperform at Daiwa

TODAY'S FREE FLY STORIES

Periodicals
Sibanye-Stillwater nears $1B deal to buy two Brazilian miners, WSJ reports » 19:57
10/24/21
10/24
19:57
10/24/21
19:57
SBSW

Sibanye Stillwater

$14.46 /

+0.065 (+0.45%)

Sibanye-Stillwater (SBSW)…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
SBSW Sibanye Stillwater
$14.46 /

+0.065 (+0.45%)

SBSW Sibanye Stillwater
$14.46 /

+0.065 (+0.45%)

10/12/21 Deutsche Bank
Sibanye Stillwater initiated with a Buy at Deutsche Bank
02/16/21 RBC Capital
Sibanye Stillwater price target raised to $28 from $25 at RBC Capital
11/27/20 Citi
Sibanye Stillwater initiated with a Buy at Citi
11/11/20 BMO Capital
Sibanye Stillwater initiated with an Outperform at BMO Capital
SBSW Sibanye Stillwater
$14.46 /

+0.065 (+0.45%)

Recommendations
RLI Corp. price target raised to $125 from $120 at Keefe Bruyette » 19:24
10/24/21
10/24
19:24
10/24/21
19:24
RLI

RLI Corp.

$108.21 /

+0.615 (+0.57%)

Keefe Bruyette analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
RLI RLI Corp.
$108.21 /

+0.615 (+0.57%)

RLI RLI Corp.
$108.21 /

+0.615 (+0.57%)

10/19/21
Fly Intel: Top five analyst upgrades
10/19/21 Keefe Bruyette
RLI Corp. upgraded to Outperform from Market Perform at Keefe Bruyette
09/30/21 RBC Capital
RLI Corp. price target lowered to $110 from $115 at RBC Capital
04/23/21 RBC Capital
RLI Corp. price target raised to $115 from $110 at RBC Capital
RLI RLI Corp.
$108.21 /

+0.615 (+0.57%)

Downgrade
WSFS Financial downgraded to Market Perform from Outperform at Keefe Bruyette » 19:23
10/24/21
10/24
19:23
10/24/21
19:23
WSFS

WSFS Financial

$55.60 /

+0.13 (+0.23%)

Keefe Bruyette analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
WSFS WSFS Financial
$55.60 /

+0.13 (+0.23%)

WSFS WSFS Financial
$55.60 /

+0.13 (+0.23%)

08/20/21 Seaport Global
WSFS Financial initiated with a Neutral at Seaport Global
07/30/21 Keefe Bruyette
Bryn Mawr Bank upgraded to Outperform from Market Perform at Keefe Bruyette
07/22/21 Keefe Bruyette
WSFS Financial upgraded to Outperform from Market Perform at Keefe Bruyette
03/12/21 Keefe Bruyette
Bryn Mawr Bank downgraded on pending acquisition at Keefe Bruyette
WSFS WSFS Financial
$55.60 /

+0.13 (+0.23%)

WSFS WSFS Financial
$55.60 /

+0.13 (+0.23%)

Conference/Events
Verizon management to meet virtually with Wolfe Research » 17:40
10/24/21
10/24
17:40
10/24/21
17:40
VZ

Verizon

$52.93 /

-0.46 (-0.86%)

Virtual Meeting to be…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
VZ Verizon
$52.93 /

-0.46 (-0.86%)

VZ Verizon
$52.93 /

-0.46 (-0.86%)

10/21/21 Cowen
Verizon price target raised to $71 from $68 at Cowen
10/19/21 Deutsche Bank
Verizon resumed with a Hold at Deutsche Bank
10/13/21 Morgan Stanley
Morgan Stanley says Comcast dropping network a modest near-term negative for MSG
09/20/21 Loop Capital
Verizon initiated with a Hold, $57 target at Loop Capital
VZ Verizon
$52.93 /

-0.46 (-0.86%)

VZ Verizon
$52.93 /

-0.46 (-0.86%)

VZ Verizon
$52.93 /

-0.46 (-0.86%)

VZ Verizon
$52.93 /

-0.46 (-0.86%)

Conference/Events
Raytheon Technologies participates in a conference call with Wolfe Research » 17:38
10/24/21
10/24
17:38
10/24/21
17:38
RTX

Raytheon Technologies

$91.87 /

+0.235 (+0.26%)

Defense Analyst Maugeri…

Defense Analyst Maugeri holds a conference call with President of Raytheon Missiles & Defense, Wesley Kremer on October 28 at 3 pm hosted by Wolfe Research. Webcast Link

ShowHide Related Items >><<
RTX Raytheon Technologies
$91.87 /

+0.235 (+0.26%)

RTX Raytheon Technologies
$91.87 /

+0.235 (+0.26%)

09/21/21 Morgan Stanley
New AUKUS pact could benefit General Dynamics, Raytheon, says Morgan Stanley
08/11/21 Morgan Stanley
Raytheon Technologies price target raised to $110 from $97 at Morgan Stanley
07/29/21
Fly Intel: Top five analyst upgrades
07/29/21 Argus
Raytheon Technologies upgraded to Buy from Hold at Argus
RTX Raytheon Technologies
$91.87 /

+0.235 (+0.26%)

RTX Raytheon Technologies
$91.87 /

+0.235 (+0.26%)

RTX Raytheon Technologies
$91.87 /

+0.235 (+0.26%)

RTX Raytheon Technologies
$91.87 /

+0.235 (+0.26%)

Conference/Events
UBS technology, media, telecom analysts hold analyst/industry conference call » 17:34
10/24/21
10/24
17:34
10/24/21
17:34
CDNS

Cadence Design

$166.91 /

+1.46 (+0.88%)

Telecom, Media &…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
CDNS Cadence Design
$166.91 /

+1.46 (+0.88%)

CDNS Cadence Design
$166.91 /

+1.46 (+0.88%)

10/21/21 Wells Fargo
Cadence Design price target raised to $175 from $165 at Wells Fargo
10/20/21
Fly Intel: Top five analyst initiations
10/20/21 Needham
Cadence Design initiated with a Buy at Needham
10/19/21 Needham
Cadence Design initiated with a Buy at Needham
CDNS Cadence Design
$166.91 /

+1.46 (+0.88%)

CDNS Cadence Design
$166.91 /

+1.46 (+0.88%)

Recommendations
Ocular Therapeutix price target lowered to $20 from $27 at Piper Sandler » 17:33
10/24/21
10/24
17:33
10/24/21
17:33
OCUL

Ocular Therapeutix

$6.91 /

-3.905 (-36.12%)

Piper Sandler analyst…

Piper Sandler analyst Joseph Catanzaro lowered the firm's price target on Ocular Therapeutix to $20 from $27 and keeps an Overweight rating on the shares. The analyst notes the company announced that OTX-CSI decisively missed the primary endpoint in its Phase II dry eye study. While Catanzaro was optimistic based on some early Phase I data and more so the mechanism of action, OTX-CSI provided no benefit over placebo. The analyst has removed all dry eye revenues he was modeling.

ShowHide Related Items >><<
OCUL Ocular Therapeutix
$6.91 /

-3.905 (-36.12%)

OCUL Ocular Therapeutix
$6.91 /

-3.905 (-36.12%)

10/12/21 H.C. Wainwright
Ocular Therapeutix price target raised to $18 from $17 at H.C. Wainwright
10/11/21 Piper Sandler
AC approval 'an important milestone' for Ocular's pipeline, says Piper Sandler
08/10/21 H.C. Wainwright
Ocular Therapeutix upgraded to Buy from Neutral at H.C. Wainwright
02/12/21 Piper Sandler
Ocular Therapeutix to update on OTX-TKI's Phase I wAMD, says Piper Sandler
OCUL Ocular Therapeutix
$6.91 /

-3.905 (-36.12%)

  • 16
    Dec
OCUL Ocular Therapeutix
$6.91 /

-3.905 (-36.12%)

Conference/Events
UBS consumer goods analyst to hold analyst/industry conference call » 17:32
10/24/21
10/24
17:32
10/24/21
17:32

Consumer Goods Analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

Conference/Events
UBS consumer goods/services analysts to hold analyst/industry conference call » 17:24
10/24/21
10/24
17:24
10/24/21
17:24

Consumer Goods and…

Consumer Goods and Consumer Services Analysts discuss the current state of the supply chain on an Analyst/Industry conference call to be held on October 25 at 12 pm.

Conference/Events
PAVmed to host virtual investor meeting » 16:55
10/24/21
10/24
16:55
10/24/21
16:55
PAVM

PAVmed

$5.73 /

-0.44 (-7.13%)

Virtual Investor Meeting…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
PAVM PAVmed
$5.73 /

-0.44 (-7.13%)

PAVM PAVmed
$5.73 /

-0.44 (-7.13%)

03/29/21 Cantor Fitzgerald
PAVmed initiated with an Overweight at Cantor Fitzgerald
02/22/21 Lake Street
PAVmed price target raised to $9 from $5 at Lake Street
11/05/20
Fly Intel: Top five analyst initiations
11/05/20 Ascendiant
Ascendiant starts PAVmed with Buy on carpal tunnel potential
  • 23
    Feb
PAVM PAVmed
$5.73 /

-0.44 (-7.13%)

PAVM PAVmed
$5.73 /

-0.44 (-7.13%)

Hot Stocks
Phathom Pharmaceuticals announces data from Phase 3 PHALCON-HP trial » 16:42
10/24/21
10/24
16:42
10/24/21
16:42
PHAT

Phathom Pharmaceuticals

$29.26 /

-0.38 (-1.28%)

Phathom Pharmaceuticals…

Phathom Pharmaceuticals announced data from the PHALCON-HP Phase 3 study, the largest U.S. registrational trial ever conducted for H. pylori, that will be presented during an oral session at the ACG 2021 Annual Scientific Meeting organized by the American College of Gastroenterology, in Las Vegas, Nevada, Oct. 22-27. PHALCON-HP showed that both vonoprazan in combination with amoxicillin and clarithromycin and vonoprazan in combination with amoxicillin demonstrated superior eradication rates in all patients compared to a current standard of care therapy consisting of the proton pump inhibitor, lansoprazole, in combination with amoxicillin and clarithromycin. In the primary endpoint analyses of the PHALCON-HP study comparing the non-inferiority of vonoprazan-based therapies to lansoprazole triple therapy in patients with H. pylori without strains resistant to antibiotics, eradication rates with vonoprazan triple therapy and vonoprazan dual therapy were 84.7% and 78.5%, respectively, compared to 78.8% for lansoprazole triple therapy. In the secondary endpoint analyses comparing the superiority of vonoprazan-based therapies to lansoprazole triple therapy in all patients, eradication rates with vonoprazan triple therapy and dual therapy were 80.8% and 77.2%, respectively, compared to 68.5% for lansoprazole triple therapy. Both vonoprazan-based regimens were generally well tolerated with a safety profile comparable to lansoprazole-based triple therapy in the trial. Phathom is also presenting results from the Study of Acid-Related Disorders which explored perceptions of disease burden for H. pylori and erosive esophagitis among physicians and patients. Physicians completed an online survey recording treatment goals, preferences, satisfaction, and perceived disease burden. A subset completed chart review data of patients with H. pylori and dyspepsia or erosive esophagitis who had received a PPI as part of their treatment. The same patients completed a survey capturing data on treatment goals, satisfaction, and adherence. In this study, only 29% of physicians strongly agreed that they were satisfied with current H. pylori treatment options and 57% of patients stated they were not completely satisfied. When it came to erosive esophagitis, 84% of patients wanted long-lasting treatment options while only 44% considered their current therapy a long-lasting solution for their disease. The study uncovered many unmet needs from the perspective of both physicians and patients in the treatment of H. pylori and erosive esophagitis suggesting that new treatment options are needed.

ShowHide Related Items >><<
PHAT Phathom Pharmaceuticals
$29.26 /

-0.38 (-1.28%)

PHAT Phathom Pharmaceuticals
$29.26 /

-0.38 (-1.28%)

10/18/21 Guggenheim
Phathom Pharmaceuticals price target raised to $75 from $66 at Guggenheim
05/12/21 Goldman Sachs
Phathom Pharmaceuticals upgraded to Neutral from Sell at Goldman Sachs
02/17/21 BMO Capital
Phathom Pharmaceuticals initiated with an Outperform at BMO Capital
02/02/21 Guggenheim
Phathom Pharmaceuticals initiated with a Buy at Guggenheim
PHAT Phathom Pharmaceuticals
$29.26 /

-0.38 (-1.28%)

  • 17
    Dec
PHAT Phathom Pharmaceuticals
$29.26 /

-0.38 (-1.28%)

Conference/Events
Axcella Health to host virtual research and development day » 16:34
10/24/21
10/24
16:34
10/24/21
16:34
AXLA

Axcella Health

$2.76 /

-0.065 (-2.30%)

Virtual Research and…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
AXLA Axcella Health
$2.76 /

-0.065 (-2.30%)

AXLA Axcella Health
$2.76 /

-0.065 (-2.30%)

10/12/21 Noble Capital
Axcella Health initiated with an Outperform at Noble Capital
09/22/21 Goldman Sachs
Axcella Health downgraded to Neutral from Buy at Goldman Sachs
07/30/21 JPMorgan
Axcella downgraded to Underweight on lack of catalysts at JPMorgan
07/30/21 JPMorgan
Axcella Health downgraded to Underweight from Neutral at JPMorgan
AXLA Axcella Health
$2.76 /

-0.065 (-2.30%)

AXLA Axcella Health
$2.76 /

-0.065 (-2.30%)

AXLA Axcella Health
$2.76 /

-0.065 (-2.30%)

Conference/Events
BioVie to hold an investor webinar » 16:28
10/24/21
10/24
16:28
10/24/21
16:28
BIVI

BioVie

$5.57 /

-0.12 (-2.11%)

Management, along with…

Management, along with Drs. Kinney and Herrup, discuss the neuroinflammation and insulin resistance and new treatment approaches for Alzheimer's Disease in an Key Opinion Leader Investor Webinar on October 26 at 1:30 pm. Webcast Link

ShowHide Related Items >><<
BIVI BioVie
$5.57 /

-0.12 (-2.11%)

BIVI BioVie
$5.57 /

-0.12 (-2.11%)

05/25/21 B. Riley
BioVie price target raised to $50 from $47 at B. Riley
01/15/21 B. Riley
B. Riley starts 'largely overlooked' BioVie with Buy, $47 target
01/15/21 B. Riley
BioVie initiated with a Buy at B. Riley Securities
  • 09
    Aug
BIVI BioVie
$5.57 /

-0.12 (-2.11%)

On The Fly
Box Office Battle: 'Dune' wins weekend with strong debut despite HBO Max Play » 16:10
10/24/21
10/24
16:10
10/24/21
16:10
T

AT&T

$25.48 /

-0.27 (-1.05%)

, CMCSA

Comcast

$54.21 /

+0.18 (+0.33%)

, CMCSK

Comcast

$58.00 /

+ (+0.00%)

, SONY

Sony

$113.00 /

+0.69 (+0.61%)

, LGF.A

Lionsgate

$14.67 /

-0.01 (-0.07%)

, LGF.B

Lionsgate

$13.10 /

-0.065 (-0.49%)

, DIS

Disney

$169.42 /

-1.965 (-1.15%)

, VIACA

ViacomCBS

$40.38 /

-0.235 (-0.58%)

, VIAC

ViacomCBS

$37.52 /

-0.26 (-0.69%)

"Box Office Battle" is…

ShowHide Related Items >><<
VIACA ViacomCBS
$40.38 /

-0.235 (-0.58%)

VIAC ViacomCBS
$37.52 /

-0.26 (-0.69%)

T AT&T
$25.48 /

-0.27 (-1.05%)

SONY Sony
$113.00 /

+0.69 (+0.61%)

LGF.B Lionsgate
$13.10 /

-0.065 (-0.49%)

LGF.A Lionsgate
$14.67 /

-0.01 (-0.07%)

DIS Disney
$169.42 /

-1.965 (-1.15%)

CMCSK Comcast
$58.00 /

+ (+0.00%)

CMCSA Comcast
$54.21 /

+0.18 (+0.33%)

T AT&T
$25.48 /

-0.27 (-1.05%)

10/19/21 Citi
AT&T price target lowered to $30 from $32 at Citi
10/14/21
Fly Intel: Top five analyst upgrades
10/14/21 KeyBanc
AT&T upgraded to Sector Weight from Underweight at KeyBanc
10/14/21 KeyBanc
AT&T upgraded to Sector Weight from Underweight at KeyBanc
CMCSA Comcast
$54.21 /

+0.18 (+0.33%)

10/13/21 Morgan Stanley
Morgan Stanley says Comcast dropping network a modest near-term negative for MSG
10/12/21 Deutsche Bank
Comcast price target lowered to $64 from $68 at Deutsche Bank
10/11/21
Fly Intel: Top five analyst downgrades
10/11/21 Raymond James
Comcast downgraded to Market Perform from Outperform at Raymond James
CMCSK Comcast
$58.00 /

+ (+0.00%)

02/23/21 Credit Suisse
SeaWorld price target raised to $52 from $34 at Credit Suisse
SONY Sony
$113.00 /

+0.69 (+0.61%)

09/27/21 Cowen
Sony initiated with an Outperform at Cowen
09/10/21 Truist
Apple will likely appeal ruling in Epic case, says Truist
07/27/21 Morgan Stanley
Sony upgraded to Overweight at Morgan Stanley on animation business growth
07/27/21 Morgan Stanley
Sony upgraded to Overweight from Equal Weight at Morgan Stanley
LGF.A Lionsgate
$14.67 /

-0.01 (-0.07%)

10/13/21
Fly Intel: Top five analyst initiations
10/13/21 Benchmark
Lionsgate initiated with a Buy at Benchmark
07/22/21 Deutsche Bank
Lionsgate downgraded to Hold from Buy at Deutsche Bank
06/04/21 Barrington
Lionsgate price target raised to $27 from $16 at Barrington
LGF.B Lionsgate
$13.10 /

-0.065 (-0.49%)

06/01/21 Cowen
Lionsgate price target raised to $23 from $20 at Cowen
05/28/21 RBC Capital
Lionsgate price target raised to $17 from $13 at RBC Capital
05/26/21 Truist
Amazon's MGM deal 'a very modest negative' for Netflix/Disney, says Truist
DIS Disney
$169.42 /

-1.965 (-1.15%)

10/18/21
Fly Intel: Top five analyst downgrades
10/18/21 MoffettNathanson
Disney price target lowered to $180 from $185 at MoffettNathanson
10/18/21 Barclays
Barclays downgrades Disney on slowing of streaming growth
10/18/21 Barclays
Disney downgraded to Equal Weight from Overweight at Barclays
VIACA ViacomCBS
$40.38 /

-0.235 (-0.58%)

01/05/21 Gabelli
ViacomCBS named a best idea for 2021 at Gabelli
VIAC ViacomCBS
$37.52 /

-0.26 (-0.69%)

10/15/21 Deutsche Bank
ViacomCBS price target lowered to $44 from $45 at Deutsche Bank
08/18/21
Fly Intel: Top five analyst upgrades
08/18/21 Wells Fargo
ViacomCBS upgraded to Overweight from Equal Weight at Wells Fargo
08/06/21
Fly Intel: Top five analyst upgrades
VIACA ViacomCBS
$40.38 /

-0.235 (-0.58%)

T AT&T
$25.48 /

-0.27 (-1.05%)

SONY Sony
$113.00 /

+0.69 (+0.61%)

LGF.A Lionsgate
$14.67 /

-0.01 (-0.07%)

DIS Disney
$169.42 /

-1.965 (-1.15%)

CMCSA Comcast
$54.21 /

+0.18 (+0.33%)

  • 06
    Apr
  • 29
    Mar
  • 24
    Mar
VIACA ViacomCBS
$40.38 /

-0.235 (-0.58%)

VIAC ViacomCBS
$37.52 /

-0.26 (-0.69%)

T AT&T
$25.48 /

-0.27 (-1.05%)

SONY Sony
$113.00 /

+0.69 (+0.61%)

LGF.A Lionsgate
$14.67 /

-0.01 (-0.07%)

DIS Disney
$169.42 /

-1.965 (-1.15%)

CMCSK Comcast
$58.00 /

+ (+0.00%)

CMCSA Comcast
$54.21 /

+0.18 (+0.33%)

T AT&T
$25.48 /

-0.27 (-1.05%)

SONY Sony
$113.00 /

+0.69 (+0.61%)

LGF.A Lionsgate
$14.67 /

-0.01 (-0.07%)

DIS Disney
$169.42 /

-1.965 (-1.15%)

CMCSK Comcast
$58.00 /

+ (+0.00%)

CMCSA Comcast
$54.21 /

+0.18 (+0.33%)

VIAC ViacomCBS
$37.52 /

-0.26 (-0.69%)

T AT&T
$25.48 /

-0.27 (-1.05%)

SONY Sony
$113.00 /

+0.69 (+0.61%)

DIS Disney
$169.42 /

-1.965 (-1.15%)

CMCSA Comcast
$54.21 /

+0.18 (+0.33%)

Conference/Events
Aslan Pharmaceuticals to hold an investor webinar » 16:10
10/24/21
10/24
16:10
10/24/21
16:10
ASLN

Aslan Pharmaceuticals

$1.47 /

-0.12 (-7.55%)

Management discusses the…

Management discusses the recently announced, positive topline data from the Company's randomized, double-blind, placebo-controlled, 8-week, multiple-ascending-dose (MAD) Phase 1 study of ASLAN004 for treatment of moderate-to-severe atopic dermatitis (AD) in an Investor Webinar to be held on October 25 at 10 am. Webcast Link

ShowHide Related Items >><<
ASLN Aslan Pharmaceuticals
$1.47 /

-0.12 (-7.55%)

ASLN Aslan Pharmaceuticals
$1.47 /

-0.12 (-7.55%)

09/27/21 Piper Sandler
Piper buyers on Aslan weakness, thinks ASLAN-004 can be competitive
07/09/21 Jefferies
Aslan Pharmaceuticals initiated with a Buy at Jefferies
05/11/21 Piper Sandler
Aslan Pharmaceuticals price target lowered to $8 from $9 at Piper Sandler
03/17/21 H.C. Wainwright
Aslan Pharmaceuticals price target raised to $8 from $5 at H.C. Wainwright
ASLN Aslan Pharmaceuticals
$1.47 /

-0.12 (-7.55%)

  • 03
    Mar
ASLN Aslan Pharmaceuticals
$1.47 /

-0.12 (-7.55%)

ASLN Aslan Pharmaceuticals
$1.47 /

-0.12 (-7.55%)

Periodicals
Tesla raises price of Model X, Model S variants by $5,000, Reuters says » 15:39
10/24/21
10/24
15:39
10/24/21
15:39
TSLA

Tesla

$909.51 /

+15.82 (+1.77%)

Tesla has increased the…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
TSLA Tesla
$909.51 /

+15.82 (+1.77%)

TSLA Tesla
$909.51 /

+15.82 (+1.77%)

09:08 Today Morgan Stanley
Morgan Stanley sees several reasons why Tesla's Q3 'is bearish' for Autos
10/21/21 RBC Capital
Tesla price target raised to $800 from $755 at RBC Capital
10/21/21 Credit Suisse
Tesla price target raised to $830 from $800 at Credit Suisse
10/21/21 Wedbush
Tesla price target raised to $1,100 from $1,000 at Wedbush
TSLA Tesla
$909.51 /

+15.82 (+1.77%)

TSLA Tesla
$909.51 /

+15.82 (+1.77%)

TSLA Tesla
$909.51 /

+15.82 (+1.77%)

TSLA Tesla
$909.51 /

+15.82 (+1.77%)

On The Fly
Week in SPAC News: Digital World soars after Trump Media deal » 15:36
10/24/21
10/24
15:36
10/24/21
15:36
TWTR

Twitter

$62.24 /

-3.16 (-4.83%)

, FB

Facebook

$324.68 /

-17.41 (-5.09%)

, DWAC

Digital World Acquisition

$94.00 /

+48.06 (+104.61%)

, WMT

Walmart

$148.34 /

+1.485 (+1.01%)

, SVFC

SVF Investment Corp. 3

$9.89 /

-0.035 (-0.35%)

, BOWX

BowX Acquisition

$10.39 /

+ (+0.00%)

, WE

WeWork

$13.00 /

+1.245 (+10.60%)

, DCRN

Decarbonization Plus Acquisition Corp. II

$9.94 /

+0.025 (+0.25%)

, NHIC

NewHold Investment Corp. II

/

+

, GTAC

Global Technology Acquisition I

/

+

, THAC

Thrive Acquisition

/

+

, XFIN

ExcelFin Acquisition

/

+

, GOGN

GoGreen Investments

/

+

, NCAC

Newcourt Acquisition

/

+

, ESAC

Esgen Acquisition

/

+

, WWAC

Worldwide Webb Acquisition

/

+

, AXH

Industrial Human Capital

/

+

, ACAQ

Athena Consumer Acquisition

/

+

, FEXD

Fintech Ecosystem Development

/

+

, BMAQ

Blockchain Moon Acquisition

/

+

, SMAP

SportsMap Tech Acquisition

/

+

In SPAC news this week,…

ShowHide Related Items >><<
WMT Walmart
$148.34 /

+1.485 (+1.01%)

WE WeWork
$13.00 /

+1.245 (+10.60%)

TWTR Twitter
$62.24 /

-3.16 (-4.83%)

NHIC NewHold Investment Corp. II
/

+

FB Facebook
$324.68 /

-17.41 (-5.09%)

DWAC Digital World Acquisition
$94.00 /

+48.06 (+104.61%)

DCRN Decarbonization Plus Acquisition Corp. II
$9.94 /

+0.025 (+0.25%)

BOWX BowX Acquisition
$10.39 /

+ (+0.00%)

TWTR Twitter
$62.24 /

-3.16 (-4.83%)

09:12 Today BofA
Twitter price target lowered to $82 from $90 at BofA
10/22/21 Piper Sandler
Snap results raise uncertainty for digital advertising, says Piper Sandler
10/18/21 Wedbush
Wedbush continues to favor Google, Snap headed into quarterly results
10/07/21 Oppenheimer
AppLovin price target raised to $95 from $75 at Oppenheimer
FB Facebook
$324.68 /

-17.41 (-5.09%)

10/18/21 Credit Suisse
Facebook algorithm, service outages grab investor attention, says Credit Suisse
10/15/21 Evercore ISI
Facebook added to 'Tactical Underperform List' at Evercore ISI
DWAC Digital World Acquisition
$94.00 /

+48.06 (+104.61%)

WMT Walmart
$148.34 /

+1.485 (+1.01%)

10/19/21
Fly Intel: Top five analyst upgrades
10/18/21 Goldman Sachs
Walmart upgraded to Conviction Buy from Buy at Goldman Sachs
10/06/21 Morgan Stanley
Affirm relationship with Target not new, says Morgan Stanley
09/29/21 Piper Sandler
Piper ups Impinj target to $75 after finding RFID in Walmart
SVFC SVF Investment Corp. 3
$9.89 /

-0.035 (-0.35%)

BOWX BowX Acquisition
$10.39 /

+ (+0.00%)

WE WeWork
$13.00 /

+1.245 (+10.60%)

DCRN Decarbonization Plus Acquisition Corp. II
$9.94 /

+0.025 (+0.25%)

10/21/21 Roth Capital
Decarbonization Plus Acquisition Corp. II initiated with a Buy at Roth Capital
10/19/21 DA Davidson
Decarbonization Plus Acquisition Corp. II initiated with a Buy at DA Davidson
10/05/21 Fox Advisors
Decarbonization Plus Acquisition Corp. II initiated with an Overweight at Fox Advisors
NHIC NewHold Investment Corp. II
/

+

07/08/21
NewHold Investment Corp. participates in a conference call hosted by Northland
06/29/21 Northland
NewHold Investment Corp. initiated with an Outperform at Northland
GTAC Global Technology Acquisition I
/

+

THAC Thrive Acquisition
/

+

XFIN ExcelFin Acquisition
/

+

GOGN GoGreen Investments
/

+

NCAC Newcourt Acquisition
/

+

ESAC Esgen Acquisition
/

+

WWAC Worldwide Webb Acquisition
/

+

AXH Industrial Human Capital
/

+

ACAQ Athena Consumer Acquisition
/

+

FEXD Fintech Ecosystem Development
/

+

BMAQ Blockchain Moon Acquisition
/

+

SMAP SportsMap Tech Acquisition
/

+

WMT Walmart
$148.34 /

+1.485 (+1.01%)

TWTR Twitter
$62.24 /

-3.16 (-4.83%)

FB Facebook
$324.68 /

-17.41 (-5.09%)

WMT Walmart
$148.34 /

+1.485 (+1.01%)

TWTR Twitter
$62.24 /

-3.16 (-4.83%)

FB Facebook
$324.68 /

-17.41 (-5.09%)

WMT Walmart
$148.34 /

+1.485 (+1.01%)

TWTR Twitter
$62.24 /

-3.16 (-4.83%)

SVFC SVF Investment Corp. 3
$9.89 /

-0.035 (-0.35%)

FB Facebook
$324.68 /

-17.41 (-5.09%)

DWAC Digital World Acquisition
$94.00 /

+48.06 (+104.61%)

WMT Walmart
$148.34 /

+1.485 (+1.01%)

WE WeWork
$13.00 /

+1.245 (+10.60%)

TWTR Twitter
$62.24 /

-3.16 (-4.83%)

NHIC NewHold Investment Corp. II
/

+

FB Facebook
$324.68 /

-17.41 (-5.09%)

BOWX BowX Acquisition
$10.39 /

+ (+0.00%)

Recommendations
Snap price target lowered to $67 from $80 at BofA » 09:26
10/24/21
10/24
09:26
10/24/21
09:26
SNAP

Snap

$55.14 /

-20.05 (-26.67%)

BofA analyst Justin Post…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
SNAP Snap
$55.14 /

-20.05 (-26.67%)

SNAP Snap
$55.14 /

-20.05 (-26.67%)

10/22/21 RBC Capital
Snap price target lowered to $70 from $88 at RBC Capital
10/22/21 Truist
Snap price target lowered to $75 from $100 at Truist
10/22/21 Jefferies
Snap price target lowered to $76 from $90 at Jefferies
10/22/21 KeyBanc
Snap price target lowered to $85 from $90 at KeyBanc
SNAP Snap
$55.14 /

-20.05 (-26.67%)

SNAP Snap
$55.14 /

-20.05 (-26.67%)

SNAP Snap
$55.14 /

-20.05 (-26.67%)

SNAP Snap
$55.14 /

-20.05 (-26.67%)

Recommendations
Beyond Meat price target lowered to $80 from $95 at BofA » 09:24
10/24/21
10/24
09:24
10/24/21
09:24
BYND

Beyond Meat

$95.78 /

-12.66 (-11.67%)

BofA analyst Bryan…

BofA analyst Bryan Spillane lowered the firm's price target on Beyond Meat to $80 from $95 and keeps an Underperform rating on the shares. The analyst pointed out on a research note on Friday that the company has issued a press release updating its Q3 sales outlook to $106M versus prior outlook of $120M-$140M.

ShowHide Related Items >><<
BYND Beyond Meat
$95.78 /

-12.66 (-11.67%)

BYND Beyond Meat
$95.78 /

-12.66 (-11.67%)

10/22/21 Goldman Sachs
Beyond Meat price target lowered to $85 from $99 at Goldman Sachs
10/05/21 Piper Sandler
Piper teen survey shows clothing outranked food for first time since 2014
09/16/21
Fly Intel: Top five analyst downgrades
09/16/21 Piper Sandler
Piper Sandler downgrades Beyond Meat to sell, says estimates too high
BYND Beyond Meat
$95.78 /

-12.66 (-11.67%)

BYND Beyond Meat
$95.78 /

-12.66 (-11.67%)

BYND Beyond Meat
$95.78 /

-12.66 (-11.67%)

BYND Beyond Meat
$95.78 /

-12.66 (-11.67%)

Recommendations
American Express price target raised to $189 from $178 at BofA » 09:21
10/24/21
10/24
09:21
10/24/21
09:21
AXP

American Express

$187.17 /

+9.76 (+5.50%)

BofA analyst Mihir Bhatia…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
AXP American Express
$187.17 /

+9.76 (+5.50%)

AXP American Express
$187.17 /

+9.76 (+5.50%)

08:59 Today Credit Suisse
American Express price target raised to $155 from $150 at Credit Suisse
09/16/21
Fly Intel: Top five analyst upgrades
09/16/21 BofA
American Express upgraded to Neutral at BofA on accelerating QTD billings
09/16/21 BofA
American Express upgraded to Neutral from Underperform at BofA
AXP American Express
$187.17 /

+9.76 (+5.50%)

AXP American Express
$187.17 /

+9.76 (+5.50%)

AXP American Express
$187.17 /

+9.76 (+5.50%)

AXP American Express
$187.17 /

+9.76 (+5.50%)

Recommendations
Whirlpool price target lowered to $240 from $250 at BofA » 09:19
10/24/21
10/24
09:19
10/24/21
09:19
WHR

Whirlpool

$213.67 /

+6.23 (+3.00%)

BofA lowered the…

BofA lowered the firm's price target on Whirlpool to $240 from $250 and keeps a Neutral rating on the shares following quarterly results. The analyst said in a research note on Friday that he believes the U.S. appliance industry is moving past peak volumes and margins.

ShowHide Related Items >><<
WHR Whirlpool
$213.67 /

+6.23 (+3.00%)

WHR Whirlpool
$213.67 /

+6.23 (+3.00%)

07/23/21 RBC Capital
Whirlpool price target raised to $222 from $210 at RBC Capital
07/07/21 Goldman Sachs
Goldman says 'limited' July 4th promotions positive for Whirlpool
04/23/21 RBC Capital
Whirlpool price target raised to $210 from $201 at RBC Capital
04/15/21 Raymond James
Raymond James says AHAM Q1 U.S. 'core 6' appliance wholesale shipments up 18%
WHR Whirlpool
$213.67 /

+6.23 (+3.00%)

WHR Whirlpool
$213.67 /

+6.23 (+3.00%)

WHR Whirlpool
$213.67 /

+6.23 (+3.00%)

WHR Whirlpool
$213.67 /

+6.23 (+3.00%)

Recommendations
Simon Property price target raised to $165 from $150 at BofA » 09:15
10/24/21
10/24
09:15
10/24/21
09:15
SPG

Simon Property

$145.13 /

+1.125 (+0.78%)

BofA analyst Craig…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
SPG Simon Property
$145.13 /

+1.125 (+0.78%)

SPG Simon Property
$145.13 /

+1.125 (+0.78%)

09/22/21
Fly Intel: Top five analyst upgrades
09/22/21 Argus
Simon Property upgraded to Buy from Hold at Argus
09/22/21 Argus
Simon Property upgraded to Buy from Hold at Argus
09/01/21 Piper Sandler
Simon Property price target raised to $165 from $150 at Piper Sandler
SPG Simon Property
$145.13 /

+1.125 (+0.78%)

  • 19
    Nov
SPG Simon Property
$145.13 /

+1.125 (+0.78%)

SPG Simon Property
$145.13 /

+1.125 (+0.78%)

Recommendations
Twitter price target lowered to $82 from $90 at BofA » 09:12
10/24/21
10/24
09:12
10/24/21
09:12
TWTR

Twitter

$62.24 /

-3.16 (-4.83%)

BofA analyst Justin Post…

BofA analyst Justin Post lowered the firm's price target on Twitter to $82 from $90 and keeps a Buy rating on the shares ahead of quarterly results. The analyst said in a research note on Friday that he sees potential for relative strength versus peers from high exposure to brand ad spending, with a small IDFA offset. For Q4, Post estimates revenue to grow 23% year-over-year to $1.59B and expects Q4 guidance at $1.50B-$1.58B. Twitter recently indicated that the company plans to replenish MoPub revenue loss in the 2023 guide, which implies confidence in core business revenue trajectory. However, Twitter also suggested accelerated product development, so margin pressure in Q4 guidance is a risk, the analyst highlights.

ShowHide Related Items >><<
TWTR Twitter
$62.24 /

-3.16 (-4.83%)

TWTR Twitter
$62.24 /

-3.16 (-4.83%)

10/22/21 Piper Sandler
Snap results raise uncertainty for digital advertising, says Piper Sandler
10/18/21 Wedbush
Wedbush continues to favor Google, Snap headed into quarterly results
10/07/21 Oppenheimer
AppLovin price target raised to $95 from $75 at Oppenheimer
09/13/21
Fly Intel: Top five analyst initiations
TWTR Twitter
$62.24 /

-3.16 (-4.83%)

TWTR Twitter
$62.24 /

-3.16 (-4.83%)

TWTR Twitter
$62.24 /

-3.16 (-4.83%)

TWTR Twitter
$62.24 /

-3.16 (-4.83%)

Recommendations
Morgan Stanley sees several reasons why Tesla's Q3 'is bearish' for Autos » 09:08
10/24/21
10/24
09:08
10/24/21
09:08
TSLA

Tesla

$909.51 /

+15.82 (+1.77%)

Morgan Stanley analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
TSLA Tesla
$909.51 /

+15.82 (+1.77%)

TSLA Tesla
$909.51 /

+15.82 (+1.77%)

10/21/21 RBC Capital
Tesla price target raised to $800 from $755 at RBC Capital
10/21/21 Credit Suisse
Tesla price target raised to $830 from $800 at Credit Suisse
10/21/21 Wedbush
Tesla price target raised to $1,100 from $1,000 at Wedbush
10/21/21 Roth Capital
Tesla price target raised to $250 from $150 at Roth Capital
TSLA Tesla
$909.51 /

+15.82 (+1.77%)

TSLA Tesla
$909.51 /

+15.82 (+1.77%)

TSLA Tesla
$909.51 /

+15.82 (+1.77%)

TSLA Tesla
$909.51 /

+15.82 (+1.77%)

Recommendations
Apple iPhone waits remain extended amid supply constraints, says Credit Suisse » 09:02
10/24/21
10/24
09:02
10/24/21
09:02
AAPL

Apple

$148.69 /

-0.76 (-0.51%)

Credit Suisse analyst…

Credit Suisse analyst Matthew Cabral notes that as of Friday 10/22, wait times for the iPhone 13 Pro/Max remain similar to last Friday, continuing to be the longest in at least four years at greater than four weeks across the board. Waits for the base iPhone 13/13 mini were also stable, largely unchanged at 1-2 weeks for all SKUs, he adds. Cabral thinks supply constraints are a significant driver of the extended waits year-over-year, though Apple's demand is likely durable given the wider stickiness of the iOS ecosystem. The analyst has a Neutral rating and a price target of $150 on the shares.

ShowHide Related Items >><<
AAPL Apple
$148.69 /

-0.76 (-0.51%)

AAPL Apple
$148.69 /

-0.76 (-0.51%)

10/22/21 Truist
Snap price target lowered to $75 from $100 at Truist
10/22/21 Jefferies
Snap price target lowered to $76 from $90 at Jefferies
10/19/21 JPMorgan
JPMorgan sees Q4 beat for Apple with 'deja-vu' guidance for Q1
10/19/21 DA Davidson
Apple price target raised to $175 from $167 at DA Davidson
AAPL Apple
$148.69 /

-0.76 (-0.51%)

AAPL Apple
$148.69 /

-0.76 (-0.51%)

AAPL Apple
$148.69 /

-0.76 (-0.51%)

AAPL Apple
$148.69 /

-0.76 (-0.51%)

AAPL Apple
$148.69 /

-0.76 (-0.51%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.